Healthcare at a Crossroads: Winners and Losers in 2026
A significant shift is brewing in the American healthcare landscape, set to fully materialize in 2026. While some will experience relief from soaring costs thanks to landmark legislation, others face the prospect of increased financial burdens as crucial support programs expire. This isn’t a future problem; the changes are already beginning to unfold, creating a two-tiered system with potentially far-reaching consequences.
Medicare’s Newfound Bargaining Power
For millions of Medicare beneficiaries, 2026 promises tangible savings. The Inflation Reduction Act, signed into law in 2022, empowers Medicare to negotiate prices for some of the most expensive prescription drugs. Starting January 1st, these negotiated prices will apply to ten key medications, including life-saving blood thinners like Eliquis and Xarelto, and diabetes drugs such as Jardiance and Januvia. Approximately 9 million older adults rely on these medications.
The impact is projected to be substantial. A recent AARP report estimates out-of-pocket costs for these drugs will fall by over 50% on average, with seven costing less than $100 per month. The Centers for Medicare & Medicaid Services (CMS) projects a total savings of $1.5 billion for Medicare enrollees next year.
Did you know? The Inflation Reduction Act also caps annual out-of-pocket prescription drug spending for Medicare at $2,000 (rising to $2,100 in 2026), and insulin costs are capped at $35 per month.
Tom Howie, 81, of Flint, Michigan, exemplifies the positive change. After years of spending up to $8,000 out-of-pocket before reaching Medicare’s catastrophic coverage threshold, he hit the $2,000 cap by May this year. “It’s a big difference,” says Howie, who lives on a fixed income. “I just get my Social Security, basically, and then I have some money from my 401(k).”
The Shadow Side: ACA and Medicaid Uncertainty
However, the picture isn’t uniformly bright. The expiration of Affordable Care Act (ACA) tax credits and potential cuts to Medicaid threaten to offset Medicare’s gains for millions of others. These changes stem from decisions made by both the Biden and Trump administrations.
Enhanced ACA subsidies, implemented to make health insurance more affordable, are set to expire as Republicans in Congress have resisted extending them. KFF analysis suggests premiums could increase by as much as 114% for some individuals when combined with insurer rate hikes. Early enrollment data already indicates people are leaving ACA coverage or opting for cheaper, less comprehensive plans.
Furthermore, changes to Medicaid funding, enacted under the Trump administration, are taking effect. The end of a financial incentive for states to expand Medicaid leaves low-income adults in ten states in a “coverage gap” – ineligible for Medicaid but unable to afford ACA coverage. More sweeping Medicaid changes, including work requirements, are slated for 2027.
Pro Tip: If you receive health insurance through the ACA marketplace, carefully review your options during open enrollment and explore all available subsidies and cost-sharing reductions.
The Complicated Impact of Drug Pricing Deals
The Trump administration has also pursued a different approach to lowering drug costs, focusing on direct negotiations with pharmaceutical companies. Through the TrumpRx.gov website, consumers can access lower prices on certain medications offered directly by manufacturers in exchange for tariff relief. Deals with Novo Nordisk and Eli Lilly, makers of Wegovy and Zepbound, aim to reduce the cost of these weight-loss drugs.
However, experts like Larry Levitt of KFF caution that these deals are voluntary and could be reversed. “President Trump has been using the threat of tariffs as leverage with drug companies,” Levitt explains. “If that threat goes away in the future, there won’t be anything holding drug companies back from raising prices again.”
Moreover, the Inflation Reduction Act’s price negotiation provisions have had an unintended consequence: drugmakers are increasingly setting higher initial prices for new medications to mitigate the impact of future price controls. A recent report by the Institute for Clinical and Economic Review found that average net launch prices for new drugs increased by 51% between 2022 and 2024.
Looking Ahead: A Call for Policy Solutions
The healthcare landscape in 2026 will be defined by these competing forces. While Medicare beneficiaries stand to benefit from lower drug costs, those relying on the ACA and Medicaid face increased uncertainty. The long-term impact will depend on future policy decisions, including potential extensions of ACA subsidies and adjustments to Medicaid funding.
Frequently Asked Questions
- Will the Inflation Reduction Act affect all prescription drugs? No, it currently applies to a limited number of the most expensive drugs covered by Medicare.
- What happens if the ACA subsidies expire? Premiums for ACA plans could significantly increase, potentially making coverage unaffordable for many.
- Are there any resources available to help me understand my healthcare options? Yes, visit Healthcare.gov or contact your state’s health insurance marketplace.
- What is TrumpRx.gov? It’s a website connecting consumers to drugmakers offering direct-pay discounts.
What are your thoughts on the changing healthcare landscape? Share your concerns and experiences in the comments below!
Explore more articles on healthcare policy and affordability here.
Subscribe to our newsletter for the latest updates on healthcare news and trends here.
Worth a look